Adalimumab

Regulatory compliance: Developed from a cell line with DMF filing, ensuring global regulatory readiness and streamlined submissions. High titer: Optimized cell line and process deliver consistently strong productivity, supporting cost-efficient large-scale manufacturing. High degree of similarity: Proven analytical comparability to the reference product, ensuring regulatory and clinical acceptance. Favorable license terms: Flexible, partner-friendly licensing framework designed to accelerate collaboration. Broad media adaptability: Cell line performs robustly across multiple media platforms, facilitating scalable and transferable upstream development.